BioCryst Pharmaceuticals (BCRX) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vericel (VCEL) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 23.0% versus a gain of 20.9%. Over five years, VCEL leads with a -19.8% price change compared with -44.5% for BCRX. BioCryst Pharmaceuticals is the larger company by market cap ($2.15 billion vs $2.09 billion), about 1.0 times the size.
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (8.9x vs 48.2x for Vericel).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | VCEL |
|---|---|---|
| Share price | $8.40 | $40.74 |
| Market cap | $2.15B | $2.09B |
| 1-day change | +5.66% | +1.72% |
| YTD return | +7.69% | +13.14% |
| 1-year return | +20.86% | +23.04% |
| 5-year return | -44.48% | -19.79% |
| P/E ratio (TTM) | — | 84.88 |
| Forward P/E | 8.94 | 48.16 |
| EPS (TTM) | $-1.40 | $0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.22 | $49.32 |
| 52-week low | $6.00 | $28.95 |
| Distance from 52-week high | -25.13% | -17.40% |
| Analyst consensus | buy | none |
| Avg. price target upside | +146.79% | +48.67% |
| Average volume | 4.09M | 503.13K |
| Shares outstanding | 255.54M | 51.21M |
| Employees | 435 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
BCRX vs VCEL FAQ
Which is bigger, BioCryst Pharmaceuticals or Vericel?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.15B compared with $2.09B for Vericel (VCEL).
Which stock has performed better over the past year, BCRX or VCEL?
VCEL returned +23.04% over the past 12 months, compared with +20.86% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Vericel in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.